A Phase 3 interventional study of Ixekizumab and Placebo in Spondyloarthritis, sponsored by Eli Lilly and Company. Completed at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Spondylarthritis with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Spondylarthritis · United States.
Among the 27 studies in Spondylarthritis with a site in United States, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 14th registered.
203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.
Browse Spondylarthritis studies →6 of the 27 studies in Spondylarthritis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
Oregon Health and Science University · Sites in United States
Ages 5–85 · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 2–99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 341 is above the median of 108 across 106 interventional studies indexed under Spondylarthritis.
Median enrollment 329 across the 14 interventional studies, 134 across the 13 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Spondylarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Spondylarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.
Drug: Ixekizumab
Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.
Drug: Ixekizumab
Double Blind Period: Placebo given SC Q2W to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.
Drug: Ixekizumab · Drug: Placebo
Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14. Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52.
Drug: Ixekizumab · Drug: Adalimumab
Administered SC
Also known as: LY2439821
Administered SC
Administered SC
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Percentage of Participants Achieving an ASAS20 Response
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
Time frame: Week 16
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem). BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
Time frame: Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Percentage of Participants Achieving ASDAS Inactive Disease
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of \<1.3.
Time frame: Week 16
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score)
The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease. Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in ASAS Health Index (ASAS HI)
ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors
Time frame: Baseline, Week 16
Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP)
High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI)
The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA. 1. Lateral spinal flexion 2. Tragus-to-wall distance 3. Lumbar flexion (modified Schrober) 4. Maximal intermalleolar distance 5. Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Chest Expansion
While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Occiput to Wall Distance
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score
Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in SPARCC Enthesitis Score
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC)
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Number of Participants With Anterior Uveitis or Uveitis Flares
Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
Time frame: Baseline through Week 16
Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score
The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ)
The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = "no days" to 5 = "22-30 days." The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in the Work Productivity Activity Impairment Spondyloarthritis (WPAI-SpA) Scores
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.
Time frame: Baseline, Week 52
Number of Participants With Anti Ixekizumab Antibodies
A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10.
Time frame: Week 16
Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss)
Time frame: Week 16
Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC)
The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. "sum of all joints checked to be swollen" divided by "number of evaluable joints" and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
Time frame: Baseline, Week 16
Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score)
MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors
Time frame: Baseline, Week 16
Blinded treatment period (Week 0 to Week 16), followed by extended treatment period (Week 16 to Week 52), followed by post treatment period for a maximum of 24 weeks. Washout period occurred for only Adalimumab group for 6 weeks (Week 14 to Week 20).
| Milestone | PBO/IXE | ADA/PBO/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W |
|---|---|---|---|---|
| Started | 87 | 90 | 83 | 81 |
| Received at least one dose of study drug | 86 | 90 | 83 | 81 |
| Completed | 86 | 88 | 79 | 78 |
| Not completed | 1 | 2 | 4 | 3 |
| Withdrew: Adverse event | 0 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 |
| Milestone | PBO/IXE | ADA/PBO/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W |
|---|---|---|---|---|
| Started | 0 | 88 | 0 | 0 |
| Completed | 0 | 86 | 0 | 0 |
| Not completed | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Milestone | PBO/IXE | ADA/PBO/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W |
|---|---|---|---|---|
| Started | 86 | 86 | 79 | 78 |
| Completed | 83 | 80 | 74 | 72 |
| Not completed | 3 | 6 | 5 | 6 |
| Withdrew: Adverse event | 2 | 3 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 3 | 5 |
| Milestone | PBO/IXE | ADA/PBO/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W |
|---|---|---|---|---|
| Started | 1 | 0 | 24 | 16 |
| Completed | 0 | 0 | 11 | 8 |
| Not completed | 1 | 0 | 13 | 8 |
| Withdrew: Adverse event | 0 | 0 | 8 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 5 | 4 |
ASAS40 is defined as improvement from baseline of greater than or equal to (\>=) 40% and absolute improvement from baseline of at least 2 units in at least 3 of the following 4 domains without any worsening in the remaining domains. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using numeric rating scale (NRS) scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| percentage of participants | Placebo | Adalimumab | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response | 18.4 | 35.6 | 48.1 | 51.8 |
ASAS20 response is defined as a ≥20% improvement and an absolute improvement from baseline of ≥1 units in ≥3 of 4 following domains and no worsening of ≥20% and ≥1 unit (range 0 to 10) in the remaining domain. 1. Patient Global: How active was your spondylitis on average during the last week? score range 0 (not active) to 10 (very active). 2. Spinal Pain: How much Pain of your spine due to Ankylosing spondylitis? score ranges 0 (no pain) to 10 (severe pain). 3. Bath Ankylosing Spondylitis Functional Index: Participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants response is captured using NRS scale (range 0 to 10) with a higher score indicating worse function. 4. Inflammation based on Q5 \& Q6 mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (mean of intensity \& duration of stiffness): Score ranges from "0" (none) and "10" (very severe).
| percentage of participants | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving an ASAS20 Response | 40.2 | 58.9 | 64.2 | 68.7 |
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. Least Square (LS) Mean was calculated using mixed model repeated measures (MMRM) model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) | -0.46 ± 0.099 | -1.30 ± 0.096 | -1.43 ± 0.102 | -1.37 ± 0.101 |
The BASDAI is a participant-reported assessment consisting of 6 questions that relate to 5 major symptoms relevant to radiographic axial spondyloarthritis measuring discomfort, pain, and fatigue. 1) Fatigue, 2) Spinal pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness. participants need to score each item with a score from 0 to 10 (NRS). total score is obtained from the average of symptom scores ranging 0 (no problem) to 10 (worst problem). BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
| percentage of participants | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) Response | 17.2 | 32.2 | 42.0 | 43.4 |
The BASFI is a participant-reported assessment that establishes a participants functional baseline and subsequent response to treatment. To complete the BASFI, a participant is asked to rate the difficulty associated with 10 individual basic functional activities. Participants respond to each question using an NRS scale (range 0 to 10) with a higher score indicating worse function. The participants final BASFI score is the mean of the 10 item scores has a possible minimum value of 0 and a possible maximum value of 10, with a higher score indicating worse function. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) | -1.16 ± 0.215 | -2.14 ± 0.209 | -2.39 ± 0.222 | -2.43 ± 0.219 |
ASDAS is a composite index to assess disease activity in AS. The parameters used for the ASDAS (with CRP as acute phase reactant) are the following: 1. Total back pain 2. Patient global 3. Peripheral pain/swelling 4. Duration of morning stiffness 5. CRP in mg/L The ASDAScrp is calculated with the following equation: 0.121 × total back pain + 0.110 × patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 × Ln(CRP+1). CRP is in mg/liter, the range of other variables is from 0 to 10.Data from five variables combined to yield a score (0.6361 to no defined upper limit), where higher scores indicated higher disease activity. Ln represents the natural logarithm. ASDAS Inactive Disease is defined as a score of \<1.3.
| percentage of Participants | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Percentage of Participants Achieving ASDAS Inactive Disease | 2.3 | 15.6 | 16.0 | 10.8 |
The Berlin modification of Ankylosing Spondylitis spine MRI score for activity (ASspiMRI) scoring technique assesses inflammation in each of 23 disco-vertebral units (DVU). All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) are scored for bone marrow edema. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema \[less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)\]. The composite score ranges from 0 to 69, with higher scores reflecting worse disease. Least Squares (LS) Mean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Ankylosing Spondylitis Spinal Magnetic Resonance Imaging [ASSpiMRI] - Berlin Score) | -0.15 ± 0.323 | -2.92 ± 0.314 | -2.77 ± 0.328 | -2.54 ± 0.330 |
The SF-36 is a 36-item participant administered measure designed to be a short, multipurpose assessment of health in the areas of physical functioning, role - physical, role - emotional, bodily pain, vitality, social functioning, mental health, and general health. The 2 overarching domains of mental well- being and physical well-being are captured by the Mental Component Summary and Physical Component Summary scores. T-scores are used for analysis. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| PCS | 3.6432 ± 0.7530 | 6.9005 ± 0.7310 | 7.6952 ± 0.7768 | 7.9686 ± 0.7665 |
| MCS | 2.1229 ± 0.8431 | 2.5550 ± 0.8225 | 2.7502 ± 0.8763 | 2.5696 ± 0.8650 |
ASAS HI is a disease-specific health-index instrument designed to assess the impact of interventions for SpA, including axSpA. The 17-item instrument has scores ranging from 0 (good health) to 17 (poor health). Each item consists of one question that the participant needs to respond to with either "I agree" (score of 1) or "I do not agree" (score of 0). A score of "1" is given where the item is affirmed, indicating adverse health. All item scores are summed to give a total score or index. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in ASAS Health Index (ASAS HI) | -1.25 ± 0.300 | -2.30 ± 0.292 | -2.36 ± 0.311 | -2.74 ± 0.306 |
High sensitivity CRP is the measure of acute phase reactant. It will be measured with a high sensitivity assay at the central laboratory to help assess the effect of Ixekizumab on disease activity. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, visit and treatment-by-visit interaction as fixed factors.
| Milliragm per Litre (mg/mL) | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in the Measure of High Sensitivity C-Reactive Protein (CRP) | 1.426 ± 1.9244 | -7.202 ± 1.8688 | -5.209 ± 1.9803 | -6.565 ± 1.9582 |
The BASMI is a combined index comprising the following 5 clinical measurements of spinal mobility in participants with rad-axSpA. 1. Lateral spinal flexion 2. Tragus-to-wall distance 3. Lumbar flexion (modified Schrober) 4. Maximal intermalleolar distance 5. Cervical rotation. The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending on the result of the assessment (BASMI linear function). The average score of the 5 assessments gives the BASMI linear result. The higher the BASMI score the more severe the participants limitation of movement due to their AS. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Mobility on the Bath Ankylosing Spondylitis Metrology Index (BASMI) | -0.080 ± 0.0826 | -0.447 ± 0.0800 | -0.502 ± 0.0858 | -0.408 ± 0.0840 |
While participants have their hands resting on or behind the head, the assessor has measured the chest's encircled length by centimeter at the fourth intercostal level anteriorly. The difference between maximal inspiration and expiration in centimeters was recorded. Two tries were recorded. The better measurement (larger difference) of 2 tries (in centimeters) was used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| Centimeters (cm) | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Chest Expansion | 0.06 ± 0.152 | 0.70 ± 0.148 | 0.49 ± 0.158 | 0.67 ± 0.155 |
The participant is to make a maximum effort to touch the head against the wall when standing with heels and back against the wall (occiput). Then the distance from occiput to wall is measured. Two tries will be recorded. The better (smaller) measurement of 2 tries (in centimeters) will be used for analyses. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| cm | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Occiput to Wall Distance | -0.06 ± 0.232 | -0.72 ± 0.225 | -0.69 ± 0.240 | -0.73 ± 0.236 |
Both left and right SIJ are scored for bone marrow edema.Each side has 6 slices and each slice has 6 scoring units, and each scoring unit has a score of 0 or 1. Total SIJ SPARCC scores can range from 0 to 72 with higher scores reflecting worse disease. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in MRI Sacroiliac Joint(s) (SIJ) Spondyloarthritis Research Consortium of Canada (SPARCC) Score | 0.92 ± 0.582 | -4.21 ± 0.568 | -3.97 ± 0.590 | -4.25 ± 0.591 |
The MASES is an index used to measure the severity of enthesitis .The MASES assesses 13 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), processus spinosus L5, and Achilles tendon proximal insertion (right/left). The MASES is the sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) | -2.1 ± 0.34 | -2.6 ± 0.34 | -2.3 ± 0.36 | -2.4 ± 0.35 |
The SPARCC enthesitis is an index used to measure the severity of enthesitis. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in SPARCC Enthesitis Score | -2.1 ± 0.40 | -2.9 ± 0.40 | -2.7 ± 0.40 | -2.6 ± 0.43 |
The number of tender and painful joints was determined by examination of 46 joints (23 joints on each side of the participants body. The 46 joints are assessed and classified as tender or not tender. sum of all joints checked to be tender/painful divided by number of evaluable joints which is multiplied by 46 to obtain TJC score. The scores ranges from 0 (no tender/painful joints) to 46 (all joints tender/painful). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Severity of Peripheral Arthritis by Tender (TJC) | -2.0 ± 0.53 | -2.2 ± 0.55 | -2.5 ± 0.58 | -3.3 ± 0.58 |
Anterior uveitis is an inflammation of the middle layer of the eye which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
| Count of Participants | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Number of Participants With Anterior Uveitis or Uveitis Flares | 0 | 0 | 1 | 0 |
The Fatigue Severity NRS is a participant-administered, single-item, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine". Participants rate their fatigue (feeling tired or worn out) by circling the one number that describes their worst level of fatigue during the previous 24 hours. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in the Fatigue Numeric Rating Scale (NRS) Score | -1.4 ± 0.23 | -2.2 ± 0.23 | -2.5 ± 0.24 | -2.1 ± 0.24 |
The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research. The JSEQ assesses the frequency of sleep disturbance in 4 categories: 1) trouble falling asleep, 2) waking up several times during the night, 3) having trouble staying asleep (including waking up far too early), and 4) waking up after the usual amount of sleep feeling tired and worn out. Participants report the number of days they experience each of these problems in the past month on a 6-point Likert scale ranging from 0 = "no days" to 5 = "22-30 days." The total JSEQ score ranges from 0 to 20, with higher scores indicating greater sleep disturbance. LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in the Jenkins Sleep Evaluation Questionnaire (JSEQ) | -1.5 ± 0.41 | -2.7 ± 0.40 | -2.5 ± 0.43 | -3.0 ± 0.42 |
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from work because of SpA, hours missed from work for other reasons, hours actually worked, the degree to which SpA affected work productivity while at work, and the degree to which SpA affected activities outside of work. The WPAI-SpA has been validated in the rad-axSpA patient population. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. The computed percentage range for each sub-scale was from 0-100. Greater scores indicate greater impairment and less productivity. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Overall Work Impairment Score | -17.82 ± 3.254 | -21.44 ± 2.921 | -21.36 ± 3.061 | -24.06 ± 3.299 |
| Percentage of Activity Impairment | -14.1 ± 2.28 | -21.1 ± 2.22 | -23.0 ± 2.35 | -23.4 ± 2.30 |
ASAS-NSAID score is used to present the NSAID intake by considering the type of NSAID, the total dose, \& the number of days taking NSAID during a period of interest (PI).. ASAS-NSAID score=(equivalent NSAID score)x(days of intake during PI)x(days per week)/(PI in days). Higher scores indicate greater NSAIDs intake. 0= no intake, 100 = equivalent NSAID intake.
| score on a scale | Placebo/Ixekizumab | Adalimumab/Ixekizumab | Ixekizumab Q4W/Ixekizumab Q4W | Ixekizumab 80mg Q2W/Ixekizumab 80mg Q2W |
|---|---|---|---|---|
| Change From Baseline in ASAS-Nonsteroidal Anti-Inflammatory Drug (NSAID) Score | -10.28 ± 27.472 | -5.91 ± 20.861 | -7.62 ± 25.430 | -9.91 ± 27.940 |
A treatment emergent - antidrug antibody (TE-ADA) positive patient is defined as: a) a patient with a \>= 4-fold increase over a positive baseline antibody titer; or b) for a negative baseline titer, a patient with an increase from the baseline to a level of \>= 1:10.
| Participants | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Number of Participants With Anti Ixekizumab Antibodies | 2 | 5 | 2 | 2 |
| microgram per millilitre (μg/mL) | IXE80Q4W | IXE160/80Q4W | IXE80Q2W | IXE160/80Q2W |
|---|---|---|---|---|
| Pharmacokinetics: Trough Ixekizumab Concentration at Steady State (Ctrough ss) | 3.56 ± 56 | 3.88 ± 55 | 11.6 ± 54 | 11.3 ± 43 |
The number of swollen joints was determined by examination of 44 joints (22 joints on each side of the participants body. The 44 joints are assessed and classified as swollen or not swollen. "sum of all joints checked to be swollen" divided by "number of evaluable joints" and then multiplied by 44 to obtain SJC score. The SJC score ranges from 0 (no swollen joints) to 44 (all joints swollen). LSMean was calculated using MMRM model with treatment, geographic region, baseline CRP status, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.
| score on a scale | Placebo | Adalimumab 40mg | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Severity of Peripheral Arthritis by Swollen Joint Count (SJC) | -1.7 ± 0.55 | -2.7 ± 0.53 | -3.6 ± 0.53 | -2.7 ± 0.57 |
MRI score of spine was assessed using SPARCC method. All 23 disco-vertebral units (DVUs) of the spine (from C2 to S1) are scored for bone marrow edema. A single DVU has a scoring range of 0 to 18, bringing the maximum total score to 414, with higher scores reflecting worse disease. Scoring was performed by central readers. LSMean was calculated using ANCOVA model with treatment, geographic region, baseline CRP status and baseline value as fixed factors
| score on a scale | Placebo | Adalimumab | IXE80Q4W | IXE80Q2W |
|---|---|---|---|---|
| Change From Baseline in Magnetic Resonance Imaging (MRI) of the Spine (Spondyloarthritis Research Consortium of Canada [SPARCC] Score) | -1.51 ± 1.147 | -11.57 ± 1.113 | -11.02 ± 1.160 | -9.58 ± 1.168 |
Collected over Upto 76 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Blinded Treatment | 0/86 (0%) | 0/86 (0%) | 12/86 (14%) |
| Adalimumab 40mg - Blinded Treatment | 0/90 (0%) | 3/90 (3.3%) | 16/90 (17.8%) |
| IXE80Q2W - Blinded Treatment | 0/83 (0%) | 1/83 (1.2%) | 18/83 (21.7%) |
| IXE80Q4W - Blinded Treatment | 0/81 (0%) | 1/81 (1.2%) | 11/81 (13.6%) |
| ADA/PBO - Washout Treatment Period | 0/88 (0%) | 0/88 (0%) | 8/88 (9.1%) |
| PBO/IXE - Extended Treatment Period | 0/86 (0%) | 4/86 (4.7%) | 26/86 (30.2%) |
| ADA/PBO/IXE - Extended Treatment Period | 0/86 (0%) | 7/86 (8.1%) | 20/86 (23.3%) |
| IXE80Q2W/IXE80Q2W - Extended Treatment | 0/79 (0%) | 3/79 (3.8%) | 21/79 (26.6%) |
| IXE80Q4W/IXE80Q4W - Extended Treatment | 0/78 (0%) | 4/78 (5.1%) | 14/78 (17.9%) |
| PBO-follow-up Period | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| IXE80Q2W-follow-up Period | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| IXE80Q4W-follow-up Period | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Event | Placebo - Blinded Treatment | Adalimumab 40mg - Blinded Treatment | IXE80Q2W - Blinded Treatment | IXE80Q4W - Blinded Treatment | ADA/PBO - Washout Treatment Period | PBO/IXE - Extended Treatment Period | ADA/PBO/IXE - Extended Treatment Period | IXE80Q2W/IXE80Q2W - Extended Treatment | IXE80Q4W/IXE80Q4W - Extended Treatment | PBO-follow-up Period | IXE80Q2W-follow-up Period | IXE80Q4W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adnexal torsionReproductive system and breast disorders | 0/15 | 1/17 | 0/19 | 0/13 | 0/17 | 0/15 | 0/16 | 0/18 | 0/13 | 0/1 | 0/9 | 0/3 |
| Radius fractureInjury, poisoning and procedural complications | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 0/79 | 1/78 | 0/1 | 0/24 | 0/16 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 0/79 | 1/78 | 0/1 | 0/24 | 0/16 |
| Blood creatine phosphokinase increasedInvestigations | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 0/79 | 1/78 | 0/1 | 0/24 | 0/16 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 0/79 | 1/78 | 0/1 | 0/24 | 0/16 |
| TonsillitisInfections and infestations | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 1/79 | 0/78 | 0/1 | 0/24 | 0/16 |
| Avulsion fractureInjury, poisoning and procedural complications | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 1/79 | 0/78 | 0/1 | 0/24 | 0/16 |
| Plica syndromeMusculoskeletal and connective tissue disorders | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 1/79 | 0/78 | 0/1 | 0/24 | 0/16 |
| Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 1/79 | 0/78 | 0/1 | 0/24 | 0/16 |
| Urinary tract infectionInfections and infestations | 0/86 | 0/90 | 0/83 | 1/81 | 0/88 | 0/86 | 0/86 | 0/79 | 0/78 | 0/1 | 0/24 | 0/16 |
| Event | Placebo - Blinded Treatment | Adalimumab 40mg - Blinded Treatment | IXE80Q2W - Blinded Treatment | IXE80Q4W - Blinded Treatment | ADA/PBO - Washout Treatment Period | PBO/IXE - Extended Treatment Period | ADA/PBO/IXE - Extended Treatment Period | IXE80Q2W/IXE80Q2W - Extended Treatment | IXE80Q4W/IXE80Q4W - Extended Treatment | PBO-follow-up Period | IXE80Q2W-follow-up Period | IXE80Q4W-follow-up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocular discomfortEye disorders | 0/86 | 0/90 | 0/83 | 0/81 | 0/88 | 0/86 | 0/86 | 0/79 | 0/78 | 1/1 | 0/24 | 0/16 |
| Menopausal symptomsReproductive system and breast disorders | 0/15 | 0/17 | 0/19 | 0/13 | 0/17 | 0/15 | 0/16 | 0/18 | 0/13 | 1/1 | 0/9 | 0/3 |
| NasopharyngitisInfections and infestations | 6/86 | 6/90 | 5/83 | 6/81 | 6/88 | 17/86 | 7/86 | 7/79 | 8/78 | 0/1 | 0/24 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/86 | 1/90 | 1/83 | 0/81 | 0/88 | 0/86 | 1/86 | 1/79 | 3/78 | 0/1 | 0/24 | 2/16 |
| Upper respiratory tract infectionInfections and infestations | 4/86 | 2/90 | 4/83 | 7/81 | 2/88 | 4/86 | 4/86 | 8/79 | 4/78 | 0/1 | 1/24 | 0/16 |
| Injection site reactionGeneral disorders | 2/86 | 3/90 | 7/83 | 0/81 | 0/88 | 8/86 | 8/86 | 6/79 | 3/78 | 0/1 | 0/24 | 0/16 |
| Menstruation irregularReproductive system and breast disorders | 1/15 | 0/17 | 0/19 | 0/13 | 0/17 | 0/15 | 0/16 | 0/18 | 0/13 | 0/1 | 0/9 | 0/3 |
| Vaginal infectionInfections and infestations | 0/15 | 1/17 | 0/19 | 0/13 | 0/17 | 0/15 | 0/16 | 0/18 | 0/13 | 0/1 | 0/9 | 0/3 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/17 | 0/19 | 0/13 | 0/17 | 0/15 | 0/16 | 0/18 | 0/13 | 0/1 | 0/9 | 0/3 |
| Adnexal torsionReproductive system and breast disorders | 0/15 | 1/17 | 0/19 | 0/13 | 0/17 | 0/15 | 0/16 | 0/18 | 0/13 | 0/1 | 0/9 | 0/3 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | PBO/IXE | ADA/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W | Total |
|---|---|---|---|---|---|
| Mean | 42.7 ± 12.01 | 41.8 ± 11.44 | 41.3 ± 11.17 | 41.0 ± 12.13 | 41.7 ± 11.66 |
| Sex: Female, Male(Participants) | PBO/IXE | ADA/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W | Total |
|---|---|---|---|---|---|
| Female | 15 | 17 | 19 | 13 | 64 |
| Male | 71 | 73 | 64 | 68 | 276 |
| Ethnicity (NIH/OMB)(Participants) | PBO/IXE | ADA/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 7 | 8 | 8 | 34 |
| Not Hispanic or Latino | 67 | 74 | 68 | 66 | 275 |
| Unknown or Not Reported | 8 | 9 | 7 | 7 | 31 |
| Race (NIH/OMB)(Participants) | PBO/IXE | ADA/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 2 | 4 | 4 | 14 |
| Asian | 28 | 29 | 25 | 25 | 107 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 52 | 57 | 52 | 52 | 213 |
| More than one race | 2 | 2 | 2 | 0 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | PBO/IXE | ADA/IXE | IXE80Q2W/IXE80Q2W | IXE80Q4W/IXE80Q4W | Total |
|---|---|---|---|---|---|
| South Korea | 10 | 14 | 12 | 11 | 47 |
| Netherlands | 0 | 2 | 2 | 0 | 4 |
| United States | 5 | 3 | 4 | 3 | 15 |
| Czechia | 14 | 14 | 13 | 13 | 54 |
| Japan | 3 | 3 | 0 | 1 | 7 |
| Taiwan | 13 | 12 | 13 | 13 | 51 |
| Germany | 0 | 2 | 1 | 0 | 3 |
| Canada | 2 | 3 | 2 | 2 | 9 |
| Hungary | 3 | 2 | 2 | 3 | 10 |
| Mexico | 8 | 7 | 8 | 7 | 30 |
| Poland | 16 | 15 | 15 | 16 | 62 |
| Russia | 12 | 13 | 11 | 12 | 48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2016 to primary completion in Dec 2017, 19 months.
Results were first posted in Nov 2019, 1 year 11 months after primary completion. A results delay was requested in Jun 2018.
Of 12 phase 3 interventional studies under Spondylarthritis, half reached primary completion within 21 months of starting (the median); a quarter within 15 and three quarters within 37. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab